Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amphastar PharmaceuticalsAMPH +0.93%85 Cash-to-Debt is 0.42 as of Jun. 2026, which is 69% below its 10-year median of 1.36. GuruFocus rates AMPH with a GF Score™ of 85/100 and a GF Value™ of $36.09 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks worse than 63.89% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Amphastar Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.42.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Amphastar Pharmaceuticalscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Amphastar Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
AMPH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31 Med: 1.36 Max: 2.13
Current: 0.42
During the past 13 years, Amphastar Pharmaceuticals's highest Cash to Debt Ratio was 2.13. The lowest was 0.31. And the median was 1.36.
AMPH's Cash-to-Debt is ranked worse than 63.89% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs AMPH: 0.42
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Amphastar Pharmaceuticals Cash-to-Debt Related Terms
Amphastar Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amphastar Pharmaceuticals (AMPH) has a Cash-to-Debt of 0.42 as of Jun. 2026. This is 69% below median its historical median of 1.36. Over the past decade, Amphastar Pharmaceuticals' Cash-to-Debt has ranged from 0.31 to 2.13. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #628 out of 983 companies in the Drug Manufacturers industry, placing it in the top 63.9%.
Is Amphastar Pharmaceuticals' Cash-to-Debt too high?
Amphastar Pharmaceuticals' current Cash-to-Debt of 0.42 is 69% below median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 2.13. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Amphastar Pharmaceuticals' value of 0.42 is 56.3% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #628 out of 983 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Cash-to-Debt compare to PCRX and COLL?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #628 out of 983 companies for Cash-to-Debt. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 0.96. Amphastar Pharmaceuticals' value of 0.42 is 56.3% below this benchmark. Historically, Amphastar Pharmaceuticals' own Cash-to-Debt has ranged from 0.31 to 2.13 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 0.96, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Cash-to-Debt of 0.42 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Cash-to-Debt is 0.42, which is 69% below median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.09, compared to a current price of $23.78 — trading 34.1% below its estimated fair value. The current Cash-to-Debt is 0.42, which is 69% below median its 10-year median of 1.36 and 56.3% below the Drug Manufacturers industry median of 0.96. Amphastar Pharmaceuticals' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Cash-to-Debt is 0.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $23.78 is trading 34.1% below its estimated GF Value™ of $36.09.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Cash-to-Debt: 0.42 (69% below median its 10-year median of 1.36)
GF Value™: $36.09 vs. price of $23.78 (34.1% below fair value)
Industry Position: 56.3% below the Drug Manufacturers median (#628 of 983)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
85GF Score
Get the complete analysis for AMPH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
